Table of Contents UNITED STATES DRAFT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________________________________________________ Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-37477 _____ ...

For the quarter ended March 2025, Teladoc (TDOC) reported revenue of $629.37 million, down 2.6% over the same period last year. EPS came in at -$0.19, compared to -$0.49 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $617.67 million, representing a surprise of +1.89%. The company delivered an EPS surprise of +42.42%, with the consensus EPS estimate being -$0.33.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...

1Q-25 Quarterly Results Cautionary Note 2 • This presentation contains, and the officers of Teladoc Health, Inc. (the "Company" or "Teladoc Health") may make, "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including descriptions of the Company's business plan and strategies. These stat ...

Teladoc Health (TDOC) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Good afternoon. Thank you for attending today's Teladoc Health First Quarter twenty twenty five Earnings Call. My name is Cole and I'll be the moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. Speaker1 I'd now like to hand it Speaker0 over to Mike Menchak, Head of Investor Relations, Teladoc Health. Please go. Speaker2 Thank y ...

Exhibit 99.1 Teladoc Health Reports First Quarter 2025 Results PURCHASE, NY, April 30, 2025—Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2025 ("First Quarter 2025"). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2024 ("First Quarter 2024"). | | | Three Months Ended | | | | | --- | --- | --- | --- | --- | --- | | | | March 31, | | | | | | 2025 | | 2024 | Chang ...

PURCHASE, NY, April 30, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2025 (“First Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2024 (“First Quarter 2024”). First Quarter 2025 Highlights First Quarter 2025 revenue of $629.4 million, down 3% year-over-yearFirst Quarter 2025 net loss of $93.0 million, or $0.53 per share, ...

PURCHASE, NY, April 30, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has acquired UpLift, an innovative and tech-enabled provider of virtual mental health therapy, psychiatry and medication management services.    The acquisition supports the company’s strategy to further enhance its leadership position in virtual mental health, including the ability for consumers served by its BetterHelp segment to access benefits coverage for mental health ser ...

Core Insights - Teladoc Health Inc. will release its first quarter 2025 results on April 30, 2025, after market close [1] - A conference call to discuss the results will take place at 4:30 p.m. ET on the same day [1] Conference Call Details - U.S. participants can access the conference call by dialing 1-833-470-1428 with access code 309585 [2] - International participants can find global dial-in numbers through a provided link [2] - A live audio webcast will be available online for the conference call [2] Replay Information - A replay of the call will be available via webcast shortly after the call's completion and will remain accessible for approximately 90 days [3] Company Overview - Teladoc Health aims to empower individuals to live healthier lives by transforming the healthcare experience [4] - The company is recognized as a leader in virtual care, utilizing proprietary health signals and personalized interactions to improve health outcomes [4] - With over two decades of expertise, Teladoc Health addresses the increasing virtual care needs of consumers and healthcare professionals [4]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Core Viewpoint - The article discusses the impact of President Trump's tariffs on equity markets and highlights the importance of avoiding companies that appear undervalued but have underlying issues that make them unattractive investments. Company Analysis: Teladoc Health - Teladoc Health, a telemedicine company, has seen a significant decline in revenue growth since the pandemic, with BetterHelp's revenue dropping by 10% year over year and a 6% decrease in paying users [3][5] - Despite high growth margins, Teladoc remains unprofitable and struggles to control expenses, particularly in marketing, as it aims to establish itself in the telemedicine industry [4][6] - International revenue grew by 10% year over year to $105.1 million, but total revenue fell by 3% to $640.5 million, raising concerns about the sustainability of profitability amid rising expenses [5] - The company is exploring initiatives like third-party coverage for BetterHelp and artificial intelligence projects, but the lack of a clear path to profitability makes it a risky investment [6] Company Analysis: Tandem Diabetes Care - Tandem Diabetes Care specializes in innovative insulin pumps, such as the t:slim X2, but has faced challenges including reduced patient purchases and strong competition from larger companies like Medtronic [7][8] - The company has not been consistently profitable, and its stock has performed poorly, with a 54% decline in shares this year [8] - Trump's tariffs pose a significant risk to Tandem, as the company relies on international manufacturing, which could increase expenses and negatively impact margins and revenue due to potential inflation or recession [9][10]